Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.
Epperla N, Huang Y, Cashen AF, Vaughn JL, Hanel W, Badar T, Barta SK, Caimi PF, Sethi TK, Reddy N, Karmali R, Bello C, Chavez JC, Kothari SK, Hernandez-Ilizaliturri FJ, Svoboda J, Lansigan F, Glenn MJ, Cohen JB, Sorge C, Christian B, Herrera AF, Hamadani M, Costa LJ, Xavier AC. Epperla N, et al. Among authors: hernandez ilizaliturri fj. Blood Adv. 2024 Nov 12;8(21):5458-5466. doi: 10.1182/bloodadvances.2024013743. Blood Adv. 2024. PMID: 39213424 Free PMC article.
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang M, Cohen JB, Churnetski M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast M, Fenske T, Rao Gari SN, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Ristow K, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Gerson JN, et al. Among authors: hernandez ilizaliturri fj. Blood Adv. 2023 Dec 26;7(24):7393-7401. doi: 10.1182/bloodadvances.2023010757. Blood Adv. 2023. PMID: 37874912 Free PMC article.
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Lin LH, Ghasemi M, Burke SM, Mavis CK, Nichols JR, Torka P, Mager DE, Hernandez-Ilizaliturri FJ, Goey AKL. Lin LH, et al. Among authors: hernandez ilizaliturri fj. Target Oncol. 2023 Sep;18(5):685-695. doi: 10.1007/s11523-023-00992-4. Epub 2023 Aug 26. Target Oncol. 2023. PMID: 37632592 Free PMC article. Clinical Trial.
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.
Torka P, Groman A, Wong J, Nichols J, Kader A, Mavis C, Anampa-Guzmán A, Sait SJ, Block A, Przespolewski E, Mohr A, Lund I, McWhite K, Kostrewa J, DeMarco J, Johnson M, Darrall A, Thomas R, Sundaram S, Ghione P, Hutson A, Hernandez-Ilizaliturri FJ. Torka P, et al. Among authors: hernandez ilizaliturri fj. Blood Adv. 2023 Apr 11;7(7):1146-1155. doi: 10.1182/bloodadvances.2022008543. Blood Adv. 2023. PMID: 36375132 Free PMC article. Clinical Trial.
Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status.
Lama R, Xu C, Galster SL, Querol-García J, Portwood S, Mavis CK, Ruiz FM, Martin D, Wu J, Giorgi MC, Bargonetti J, Wang ES, Hernandez-Ilizaliturri FJ, Koudelka GB, Chemler SR, Muñoz IG, Wang X. Lama R, et al. Among authors: hernandez ilizaliturri fj. Front Oncol. 2022 Aug 5;12:933446. doi: 10.3389/fonc.2022.933446. eCollection 2022. Front Oncol. 2022. PMID: 35992795 Free PMC article.
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Torka P, Akhtar OS, Reddy NM, Baysal BE, Kader A, Groman A, Nichols J, Mavis C, Tario JD, Block AW, Sait SNJ, Ghione P, Sundaram S, Przespolewski ER, Mohr A, Lund I, Kostrewa J, McWhite K, DeMarco J, Johnson M, Darrall A, Thomas-Talley RN, Wallace PK, Neppalli V, Hutson A, Hernandez-Ilizaliturri FJ. Torka P, et al. Among authors: hernandez ilizaliturri fj. Cancer. 2022 Apr 15;128(8):1595-1604. doi: 10.1002/cncr.34106. Epub 2022 Feb 14. Cancer. 2022. PMID: 35157306 Free PMC article. Clinical Trial.
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.
Gregory GP, Kumar S, Wang D, Mahadevan D, Walker P, Wagner-Johnston N, Escobar C, Bannerji R, Bhutani D, Chang J, Hernandez-Ilizaliturri FJ, Klein A, Pagel JM, Rybka W, Yee AJ, Mohrbacher A, Huang M, Farooqui M, Marinello P, Quach H. Gregory GP, et al. Among authors: hernandez ilizaliturri fj. Blood Adv. 2022 Feb 22;6(4):1232-1242. doi: 10.1182/bloodadvances.2021005872. Blood Adv. 2022. PMID: 34972202 Free PMC article. Clinical Trial.
88 results